Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ: VTGN )

2.870 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
From Vistagen
Via Business Wire
3 Penny Stocks to Turn $999 Into $1 Million: January 2024
With our strengthening economy, you need to invest in penny stocks that will deliver high future returns, these three are your best bets. 
Via InvestorPlace
Topics Economy
Exposures Economy
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) AV-101 to Receive Patent from EPO to Treat Neuropathic Pain
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
VistaGen Therapeutics Earnings Preview
Via Benzinga
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
From Vistagen
Via Business Wire
Undervalued VistaGen Therapeutics, Analyst Highlights Potential In Anxiety Treatment
William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety... 
Via Benzinga
Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst
Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQ: VTGN), emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety disorder... 
Via Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2024 Financial Report, Corporate Update
Via Investor Brand Network
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
From Vistagen
Via Business Wire
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. 
Via Benzinga
Vistagen to Present at Stifel 2023 Healthcare Conference
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Plans to Present Positive Study Results at Conferences in November
Via Investor Brand Network
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q2 Results, Corporate Update Conference Call
Via Investor Brand Network
Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023
From Vistagen
Via Business Wire
Why Vistagen Therapeutics Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares surged 79.5% to $5.08 in pre-market trading after falling around 7% on Monday. SciSparc recently regained compliance with the Nasdaq Minimum Bid Price... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Inaugural Biotech CNS/Neuro Summit
Via Investor Brand Network
Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
From Vistagen
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Intelligent Bio Solutions Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares climbed 86.1% to $0.2248 after the company said it is considering strategic alternatives for its non-core operations. 
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Pricing of $100M Underwritten Offering
Via Investor Brand Network
Vistagen Announces Pricing of $100 Million Underwritten Offering
From Vistagen Therapeutics, Inc.
Via Business Wire
The 7 Best Short-Squeeze Stocks to Buy Now: September 2023
Explore the potential of the best short-squeeze stocks to buy now as companies attempt to prove pessimistic traders wrong. 
Via InvestorPlace
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Reports on Phase 2A Study Results Regarding Treatment of Premenstrual Dysphoric Disorder
Via Investor Brand Network
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
From Vistagen
Via Business Wire
10 Short Squeeze Stocks To Watch: Getty Images, Bitcoin Depot, Blue Apron Holdings And More
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of traders looking for the next huge move. High short interest and steep borrowing costs are among the... 
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN), Fuji Pharma Co. Ltd. (TSE: 4554) Announce Exclusive Negotiation Agreement
Via Investor Brand Network
10 Short Squeeze Stocks To Watch: Blue Apron, Getty Images, Black Rifle Coffee And More
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a new focus of traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.